Related Experiment Video

Updated: Jul 10, 2026

Intratracheal Instillation of Stem Cells in Term Neonatal Rats
04:27

Intratracheal Instillation of Stem Cells in Term Neonatal Rats

Published on: May 4, 2020

Can inhaled prostacyclin stimulate surfactant in ELBW infants?

K Olmsted1, O Oluola, A Parthiban

  • 1Department of Pediatrics, University of Kansas Medical Center, Kansas City, KS, USA.

Journal of Perinatology : Official Journal of the California Perinatal Association
|October 26, 2007
PubMed

Insights

Inhaled prostacyclin improved hypoxia in an extremely low birth weight infant with respiratory distress syndrome and pulmonary hypertension. This suggests prostacyclin may stimulate surfactant secretion, offering a novel therapeutic approach.

Area of Science:

  • Neonatal Medicine
  • Pulmonary Medicine
  • Pediatric Cardiology

Background:

  • Respiratory distress syndrome (RDS) is a primary cause of hypoxia in extremely low birth weight (ELBW) infants.
  • Pulmonary hypertension (PH) often complicates RDS, exacerbating hypoxia and challenging treatment.
  • Current therapies for RDS-associated PH, like inhaled nitric oxide, are not universally effective.

Observation:

  • A case of an ELBW infant presenting with severe RDS and refractory PH is described.
  • The infant's hypoxia persisted despite treatment with inhaled nitric oxide.
  • A significant improvement in oxygenation was observed after initiating inhaled prostacyclin therapy.

Findings:

  • Inhaled prostacyclin demonstrated efficacy in alleviating hypoxia in this ELBW infant with RDS and PH.
  • The patient's condition improved, suggesting a potential mechanism beyond traditional pulmonary vasodilation.
  • The study proposes that prostacyclin may enhance surfactant secretion, improving lung function.

Implications:

  • Inhaled prostacyclin represents a potential novel therapeutic option for refractory hypoxia in ELBW infants with RDS and PH.
  • Stimulation of surfactant secretion by prostacyclin could be a key mechanism for its beneficial effects.
  • Further research is warranted to explore the role and efficacy of inhaled prostacyclin in neonatal respiratory conditions.

More Related Videos

Development of a Neonatal Piglet Acute Lung Injury Model Recreating the Early Environment of Preterm Infant Lungs08:58

Development of a Neonatal Piglet Acute Lung Injury Model Recreating the Early Environment of Preterm Infant Lungs

Published on: October 31, 2025

Related Concept Videos

Breathing01:05

Breathing

The process of breathing, inhaling and exhaling, involves the coordinated movement of the chest wall, the lungs, and the muscles that move them. Two muscle groups with important roles in breathing are the diaphragm, located directly below the lungs, and the intercostal muscles, which lie between the ribs. When the diaphragm contracts, it moves downward, increasing the volume of the thoracic cavity and creating more room for the lungs to expand. When the intercostal muscles contract, the ribs...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Pulmonary Cycle: Exhalation01:17

Pulmonary Cycle: Exhalation

In terms of human respiration, the act of expelling air, known as exhalation (or expiration), operates on the principle of pressure gradients. During expiration, the pressure within the lungs exceeds that of the surrounding atmosphere. Under normal conditions, quiet breathing involves passive exhalation and is free of muscular contractions. This is because the exhalation process is driven by the natural elastic recoil of the lungs and chest wall, both of which have an inherent tendency to...
Inhaled Medications01:23

Inhaled Medications

Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics01:23

Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics

Respiratory symptoms, such as congestion and cough, commonly accompany respiratory tract conditions. Various medications, such as antitussives, expectorants, and mucolytics, play crucial roles in providing relief.
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla.  Benzonatate operates peripherally within the respiratory tract by anesthetizing...
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...